Clinical and Radiological Observations in a Case Series of 26 Patients with Fibrous Dysplasia

被引:0
作者
Malissa Dawn Thomsen
Lars Rejnmark
机构
[1] Aarhus University Hospital,Department of Endocrinology and Internal Medicine (MEA)
来源
Calcified Tissue International | 2014年 / 94卷
关键词
Bisphosphonate; Osteoclast; McCune–Albright syndrome; Focal bone lesion; Fibrous dysplasia;
D O I
暂无
中图分类号
学科分类号
摘要
Fibrous dysplasia (FD) is a rare disease caused by a sporadic postzygotic missense mutation that leads to abnormal fibroblast proliferation, defective osteoblast differentiation, and increased bone resorption. It may affect one or several bones. Both the mono-ostotic and polyostotic types may be associated with hyperfunctional endocrinopathies and hyperpigmentation of the skin (café-au-lait spots) in the so-called McCune–Albright syndrome (MAS). Due to its rarity, only a few case series are available, making it difficult for most clinicians to judge the severity of the disease. To improve our knowledge of FD, we reviewed all cases of FD treated at our department of endocrinology. Among 26 patients, 17 (65 %) had polyostotic FD, with four being diagnosed with MAS. Patients with polyostotic FD were diagnosed at an earlier age (median 13, range 0.5–64 years) than patients with the mono-ostotic form (median 21, 1–70 years). Craniofacial bones were affected in 80 % of cases, and 66 % complained of bone pain at the affected site, with no difference between patients with mono- and polyostotic FD. Two patients with mono-ostotic and three with polyostotic FD had cranial nerve impairments. Fourteen underwent, at least, one surgery, six (67 %) with mono-ostotic and eight (47 %) with polyostotic FD. Most received treatment with bisphosphonates, but therapy did not result in any clear relief of symptoms or radiological improvements. In conclusion, bone pain is common in patients with FD. The severity of the disease depends on affected bones as mono-ostotic may be as debilitating as polyostotic FD. In our case series, bisphosphonate treatment did not show clear beneficial effects.
引用
收藏
页码:384 / 395
页数:11
相关论文
共 246 条
  • [11] Corsi A(2005)The role of fibroblast growth factor 23 for hypophosphatemia and abnormal regulation of vitamin D metabolism in patients with McCune–Albright syndrome J Bone Miner Metab 23 231-896
  • [12] Bianco P(2005)Fibrous dysplasia pathophysiology, evaluation, and treatment J Bone Joint Surg 87 1848-1804
  • [13] Robey PG(2003)Hypophosphatemic rickets and osteomalacia in polyostotic fibrous dysplasia J Pediatr Endocrinol Metab 16 893-1690
  • [14] Kransdorf MJ(1996)Comparison of total and bone-specific alkaline phosphatase in patients with nonskeletal disorder or metabolic bone diseases Clin Chem 42 1796-E134
  • [15] Moser RP(2005)Routine isotope-dilution liquid chromatography-tandem mass spectrometry assay for simultaneous measurement of the 25-hydroxy metabolites of vitamins D Clin Chem 51 1683-509
  • [16] Gilkey FW(2013) and D J Clin Endocrinol Metab 98 E126-88
  • [17] Ippolito E(2011)Optic neuropathy in McCune–Albright syndrome: effects of early diagnosis and treatment of growth hormone excess Indian J Med Res 133 504-305
  • [18] Bray EW(1957)Fibrous dysplasia and McCune–Albright syndrome: an experience from a tertiary care centre in north India Am J Roentgenol Radium Ther Nucl Med 77 71-259
  • [19] Corsi A(2009)The roentgen features of fibrous dysplasia of the skull and facial bones: a critical analysis of thirty-nine pathologically proved cases Br J Oral Maxillofac Surg 47 302-479
  • [20] De Maio F(2012)Craniomaxillofacial fibrous dysplasia: a 10-year database 1996–2006 Clin Neurol Neurosurg 114 254-226